News

Lymphoma Research Foundation Debuts New Publication: Pulse

The Lymphoma Research Foundation is proud to launch its new flagship publication, Pulse. Published quarterly, Pulse provides the latest updates on the Foundation and its focus on lymphoma and chronic lymphocytic leukemia (CLL) research, awareness and education. Pulse will also…

Lymphoma Research Foundation Elects New Board of Director Leadership

Jeff Block and Steven Eichberg Joins Lymphoma Research Foundation Board of Directors

LRF Advocates for Patient Access to Cellular Therapies

On November 2, 2019, the Lymphoma Research Foundation sent a letter to Donald Thompson, Director, Division of Acute Care at the Centers for Medicare and Medicaid Services requesting for MS-DRG reclassification for certain cases involving the use of chimeric antigen receptor T-cell (CAR T-cell) therapies.

U.S. Food and Drug Administration Approves Acalabrutinib (CALQUENCE) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).

LRF Grantee and SAB Member Discovers Protein Responsible for Lymphoma Cell Growth

A study partially funded by the Lymphoma Research Foundation, and published in the Journal of Experimental Medicine, revealed surprising new functions for a protein called MYC.

U.S. Food and Drug Administration Approves Zanubrutinib (BRUKINSA) for Mantle Cell Lymphoma (MCL)

The U.S. Food and Drug Administration (FDA) announced it has approved the use of zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least on prior therapy.

U.S. Food and Drug Administration Approves Pegfilgrastim-bmez (Ziextenzo) for Long-Acting Oncology Supportive Care

Pegfilgrastim-bmez (Ziextenzo, Sandoz) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia for patients with nonmyeloid malignancies who are receiving myelosuppressive anti-cancer therapy.

Lymphoma Research Foundation Update on Vincristine Supply

The Lymphoma Research Foundation is aware that the supply of the vital chemotherapy medicine vincristine [Oncovin] may be limited in certain areas of the country. We understand this news is very concerning to patients who receive this medicine and their…

Buildings and Landmarks Worldwide Join the Lymphoma Research Foundation to Light Red and Raise Awareness for Blood Cancer

Lymphoma Research Foundation’s Premier Light it Red for Lymphoma Initiative Expected to Reach Millions during Blood Cancer Awareness Month The Lymphoma Research Foundation (LRF) announced its annual international Light it Red for Lymphoma awareness initiative. Since 2011, the Foundation has…

LRF Chief Executive Officer Recognized as a Leader in Healthcare

Lymphoma Research Foundation Chief Executive Officer Meghan Gutierrez was recognized as a leader in healthcare by both Crain’s New York Business and PR News. Gutierrez was among 100 women listed in Crain’s Notable Women in Health Care 2019, recognizing her…

Subscribe to Our Emails. Get lymphoma and CLL resources and updates.